Following Roche's massive acquisition, these biotech companies with promising liver disease treatments could become the next takeover targets for big pharma looking to expand in this lucrative market.
The MASH treatment market is expanding rapidly due to rising obesity rates, creating significant commercial opportunities for companies developing effective therapies in this underserved area.
These clinical-stage companies are developing cutting-edge treatments for liver and metabolic diseases, positioning themselves at the centre of a healthcare revolution that could transform patient outcomes.
Market capitalisation breakdown for the MASH stocks basket, showing concentration among the largest constituents.
ETNB: $2.20B
MDGL: $9.58B
ALT: $356.56M
Roche's massive $3.5 billion acquisition of 89bio has spotlighted the enormous commercial potential in treating liver diseases like MASH. This deal signals that big pharmaceutical companies are actively hunting for innovative biotechs in this high-growth market, creating potential opportunities for similar companies with promising drug pipelines.
These are primarily clinical-stage biopharmaceutical companies focused on developing novel therapies for liver and metabolic conditions. The market for MASH treatments is rapidly expanding due to the growing obesity epidemic, creating significant unmet medical needs that these companies are working to address.
Each company in this group has been handpicked based on their involvement in developing treatments for liver diseases and metabolic disorders. With increased M&A activity in this space, these smaller firms with promising drug candidates may become attractive acquisition targets for larger pharmaceutical companies.
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Published on September 21
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+308.86%
On average, analysts expect assets in this group to grow 308.86% over the next year.
14 of 15 assets in this group are rated Buy by professional analysts.
